Characteristics and prognosis of distant metastasis after primary treatment for early‐stage extranodal nasal‐type natural killer/T‐cell lymphoma from the China Lymphoma Collaborative Group database
Xuan Zheng,
Bao‐Lin Qu,
Xin Liu,
Qiu‐Zi Zhong,
Li‐Ting Qian,
Yong Yang,
Xiao‐Rong Hou,
Xue‐Ying Qiao,
Hua Wang,
Yuan Zhu,
Jian‐Zhong Cao,
Jun‐Xin Wu,
Tao Wu,
Su‐Yu Zhu,
Mei Shi,
Hui‐Lai Zhang,
Xi‐Mei Zhang,
Hang Su,
Yu‐Qin Song,
Jun Zhu,
Yu‐Jing Zhang,
Hui‐Qiang Huang,
Ying Wang,
Fan Chen,
Lin Yin,
Xia He,
Li‐Ling Zhang,
Ye‐Xiong Li,
Shu‐Nan Qi
Affiliations
Xuan Zheng
Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
Bao‐Lin Qu
Department of Radiation Oncology The General Hospital of Chinese People's Liberation Army Beijing China
Xin Liu
Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
Qiu‐Zi Zhong
Department of Radiation Oncology Beijing Hospital, National Geriatric Medical Center Beijing China
Li‐Ting Qian
Department of Radiation Oncology The Affiliated Provincial Hospital of Anhui Medical University Hefei China
Yong Yang
Department of Radiation Oncology Fujian Medical University Union Hospital Fuzhou China
Xiao‐Rong Hou
Department of Radiation Oncology Peking Union Medical College Hospital Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Beijing China
Xue‐Ying Qiao
Department of Radiation Oncology The Fourth Hospital of Hebei Medical University Shijiazhuang China
Hua Wang
Department of Medical Oncology Second Affiliated Hospital of Nanchang University Nanchang China
Yuan Zhu
Department of Radiation Oncology Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Zhejiang Key Laboratory of Radiation Oncology Zhejiang China
Jian‐Zhong Cao
Department of Radiation Oncology Shanxi Cancer Hospital and the Affiliated Cancer Hospital of Shanxi Medical University Taiyuan China
Jun‐Xin Wu
Department of Radiation Oncology Fujian Provincial Cancer Hospital Fuzhou China
Tao Wu
Department of Lymphoma Affiliated Hospital of Guizhou Medical University Guizhou Cancer Hospital Guiyang China
Su‐Yu Zhu
Department of Radiation Oncology Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine Changsha China
Mei Shi
Department of Radiation Oncology Xijing Hospital of Fourth Military Medical University Xi'an China
Hui‐Lai Zhang
Department of Lymphoma Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer Tianjin China
Xi‐Mei Zhang
Department of Radiation Oncology Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer Tianjin China
Hang Su
Department of Lymphoma The Fifth Medical Center of PLA General Hospital Beijing China
Yu‐Qin Song
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of LymphomaPeking University Cancer Hospital & Institute Beijing China
Jun Zhu
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of LymphomaPeking University Cancer Hospital & Institute Beijing China
Yu‐Jing Zhang
Department of Radiation Oncology Sun Yat‐sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine Guangzhou China
Hui‐Qiang Huang
Department of Medical Oncology Sun Yat‐sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine Guangzhou China
Ying Wang
Department of Radiation Oncology Chongqing University Cancer Hospital and Chongqing Cancer Hospital Chongqing China
Fan Chen
Department of Radiation OncologyAffiliated Hospital of Qinghai University Qinghai China
Lin Yin
Department of Radiation OncologyAffiliated Hospital of Qinghai University Qinghai China
Xia He
Department of Radiation Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing China
Li‐Ling Zhang
Cancer Center Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China
Ye‐Xiong Li
Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
Shu‐Nan Qi
Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
Abstract This study aimed to investigate the characteristics and prognosis of distant metastasis (DM) after primary treatment for early‐stage extranodal nasal‐type natural killer (NK)/T‐cell lymphoma (ENKTCL). A total of 1619 patients from the China Lymphoma Collaborative Group database were retrospectively reviewed. The cumulative incidence of DM was assessed using Fine and Gray's competing risk analysis. The correlation between DM sites was evaluated using phi coefficients, while DM sites were classified using hierarchical clustering. Regression analysis was used to assess the linear correlation between DM‐free survival (DMFS) and overall survival (OS). The 5‐year cumulative DM rate was 26.2%, with the highest annual hazard rate being in the first year (14.9%). The most frequent DM sites were the skin and soft tissues (SSTs, 32.4%) and distant lymph nodes (LNs, 31.3%). DM sites were categorized into four subgroups of distinct prognosis — distant LN, SST, extracutaneous site, and lymphoma‐associated hemophagocytic lymphohistiocytosis. SST or distant LN, solitary metastasis, and late‐onset DM demonstrated a relatively favorable prognosis. Contemporary chemotherapy significantly decreased DM rates and improved DMFS. Decreased DM rates were further associated with increased OS probabilities. Our findings improve the understanding of the variable clinical behaviors of early‐stage ENKTCL based on four distinct DM sites and thus provide guidance for future therapeutic decisions, metastatic surveillance, and translational trial design.